Why is there an increased risk of severe adverse perinatal outcomes after the use of clomiphene citrate for infertility treatment?

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1147683

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Clomiphene citrate (CC) has been a first line treatment for female infertility internationally since the 1960’s. However, safety studies using routine prescribing practices were never performed, and numerous data sources now indicate that CC is associated with major adverse outcomes if the fetus is inadvertently exposed. We are linking prescription data to perinatal outcomes to confirm how CC is associated with adverse events so as to inform prescriber and practice change.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $570,065.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Epidemiology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

adverse events | epidemiology | infertility therapy | pharmacoepidemiology | prescribing

Related Links